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The Michigan Department of Community Health (MDCH) stores almost 4 million dried blood spot specimens (DBS) in the Michigan 
Neonatal Biobank.1 DBS are collected from newborns 
under a mandatory public health program to screen 
for serious conditions.2 At 24 to 36 hours of age, a 
few drops of blood are taken from the baby’s heel and 
placed on a filter paper card. The card is sent to the 
state public health laboratory for testing. After testing, 
MDCH retains the spots indefinitely for the personal 
use of the patient and also, pursuant to a 2000 law,3 
for possible research.
DBS have been used in a variety of health research 
studies. Various biomarkers (e.g., DNA, RNA, and 
environmental contaminants) can be isolated and 
studied. The MDCH collection of DBS is comprised 
of entire birth cohorts dating back to 1984 allowing 
longitudinal linkages to other population-based data, 
such as the statewide cancer registry and vital records. 
For example, a future study could examine DBS to 
assess pollutants in the blood of newborns from 1984 
to present. In this article, we discuss interrelated legal 
and ethical questions that are fundamental to mak-
ing DBS available for research. We further discuss the 
“charitable trust”4 model to balance public benefits 
with respect for individuals whose DBS are used for 
research.
Recognizing the research value of these stored 
DBS, in 2008 MDCH created the Michigan BioTrust 
for Health (Michigan BioTrust) in collaboration with 
Michigan State University, University of Michigan, 
Wayne State University, and the Van Andel Institute. 
The Michigan BioTrust makes DBS specimens and 
related health data available for research to benefit 
public health. Such research can advance efforts to 
develop new disease prevention strategies, diagnos-
tic tests, and treatments for diseases. The Michigan 
BioTrust’s mission is the following: (1) to protect the 
DBS; (2) to maximize their research utility by creat-
ing a biorepository to store them indefinitely under 
optimal conditions; (3) to promote their research use; 
(4) to facilitate the retrieval of specific specimens; 
and (5) to link these specimens with other statewide 
data, while ensuring patient confidentiality and qual-
ity research
Creating the Michigan BioTrust was neither fast nor 
easy. Community engagement, public education, and 
ethical oversight were, and still are, key components. 
A Steering Committee and other workgroups grappled 
with legal, ethical, scientific and policy issues, includ-
ing the basic issue of DBS ownership. To consider 
ownership issues and the nature and scope of MDCH’s 
authority to provide DBS for research, MDCH con-
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vened a roundtable of legal, ethical, public health, and 
research representatives.
Michigan’s Public Health Code5 does not address 
ownership of DBS. It does address their control and 
require MDCH to establish policies on retention and 
destruction. DBS may be used for research as long as 
the research is conducted in a manner that preserves 
the confidentiality of the subjects and complies with 
regulations to protect human subjects from research 
risks.6 There is no direct mention of control by the 
individual, nor mention of individual consent or dis-
sent to use their DBS for research. MDCH is required 
to include a statement in its newborn screening edu-
cational pamphlet that DBS may be used for research. 
Research is recognized as a public health function 
and, as a result, MDCH is empowered to promote and 
support research to improve the health of communi-
ties and Michigan’s citizens, and to use or provide data 
to benefit the public.7 Case law regarding ownership 
and control generally holds that an individual has no 
ownership interest in tissue samples once they are col-
lected. Cases in California,8 Florida,9 and Missouri,10 
indicate that donated tissue belong to the recipient, 
suggesting that blood leftover from the Michigan 
newborn screening program belongs to the MDCH. 
However, since screening is mandatory, parents had 
not knowingly donated the leftover DBS. Further, 
regardless of ownership, there are ethical and regula-
tory requirements for consent to research and a fun-
damental right to withdraw from research.11
The roundtable concluded that under Michigan law, 
MDCH has “qualified ownership” in DBS collected for 
newborn screening, and that MDCH exercises control 
for the benefit of the child and the public. Due to this 
“qualified ownership,” MDCH is required to act as a 
fiduciary.
The roundtable’s charge included deliberating on 
the laws governing the use of DBS for research. After 
agreeing on what is explicitly allowable by law, the 
more difficult ethical question of what should be done 
within these legal parameters was addressed. How-
ever, lines between “law” and “ethics” were blurred 
by laws that require application of ethical principles, 
such as federal regulations governing human research 
subjects.12 Moreover, “qualified ownership” is more 
difficult to define than simple legal ownership, requir-
ing ethical concerns to be considered when defining 
MDCH’s authority and responsibilities.
Scholarship on charitable trusts — i.e., David Win-
ickoff and Richard Winickoff ’s “The Charitable Trust 
as a Model for Genomic Biobanks”13 — served as the 
touchstone for designing the Michigan BioTrust. In 
fact, this “trust” relationship was incorporated from 
the beginning of the project by including the term 
“BioTrust” in the project’s name, to denote MDCH’s 
relationship to the public as a trustee or steward of 
DBS. The responsibilities that accompany “qualified 
ownership” occupied much of the planning process. 
These are still being developed in some areas (e.g., 
negotiation of intellectual property rights).
Incorporating the model of a “charitable trust” had 
implications for the viability of various uses of DBS 
for research. As a state government agency, MCDH 
is responsible for the protection and promotion of 
the public’s health. This encompasses a variety of 
activities, including research that could benefit pub-
lic health. The countervailing obligation is that DBS 
should not be used for research that has no potential 
to benefit public health. For example, use of DBS for 
research on non-medically useful cosmetic products is 
not consistent with MDCH’s obligation as a trustee.
In addition to its obligation to allow research use 
of DBS only for studies that may potentially benefit 
the public’s health, MDCH is also ethically and legally 
obligated to those whose blood samples are used for 
research purposes including following research regu-
latory requirements.
Principles of ethical research from the Belmont 
Report are respect for persons, beneficence, and jus-
tice.14 Beneficence requires that the person whose 
blood is being used is not harmed, and that any pos-
sible benefits are maximized and harms minimized. 
Since BioTrust research only involves blood (and in 
some cases data) that has already been collected for 
other purposes, there is no physical risk but there are 
confidentiality risks. To address these concerns all 
directly identifying information is removed before 
DBS are sent for storage and they are labeled only with 
a barcode. Before a sample is released for research, 
the barcode is replaced with a new tracking number. 
This practice removes the researcher from the original 
identifying information, which is retained only by the 
MDCH newborn screening program. 
Justice requires fairness in who ought to receive 
the benefits of research and bear its burdens. The 
research pool is, theoretically, the entire population of 
Michigan-born children, so any potential burden that 
results from the research is unlikely to be borne by any 
one person or group. In addition, research that may 
disparage certain populations would not be allowed. 
MDCH’s role as a trustee requires that any poten-
tial benefit from the research should extend to the 
populations from which the samples were collected. 
Therefore, research using Michigan dried blood spots 
should not be allowed if those contributing samples 
to the BioTrust are unlikely to be among the eventual 
beneficiaries. The National Research Council stated, 
“In population studies, benefit to the population has 
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become one of the critical issues in determining the 
ethical justification for the study itself, and sharing 
benefits with the population is critical in preventing 
exploitation.”15
In contrast to beneficence and justice, respect for 
persons was a more difficult consideration. Respect 
for persons requires that individuals be treated as 
autonomous agents. To address this principle consent 
was debated extensively. Ultimately it was determined 
that signed consent of a parent or legal guardian for 
subsequent research use would be required (but not 
for newborn screening itself ), after October 1, 2010. 
Once a child becomes a legal adult at age 18, he or 
she can exclude their DBS from research. The MDCH 
Institutional Review Board (IRB) granted a waiver of 
consent for DBS that were already being stored before 
May 1, 2010, primarily based on the impracticability 
of obtaining consent for some 4 million DBS going as 
far back as 1984.
Although DBS may be stored for potential research, 
IRB review is still required to ensure protection of 
human research subjects. In addition, anyone can 
request that his or her blood, or the blood of his or her 
child, not be used for research purposes and it will not 
be used. For those samples collected prior to October 
1, 2010, there are educational campaigns in local ven-
ues and the media to inform Michigan citizens of the 
BioTrust project and their ability to exclude their DBS 
from research. There is a project website16 with exten-
sive information about the BioTrust, including prior 
and forthcoming research.
Several layers to protect public and individual inter-
ests are incorporated into the Michigan BioTrust’s 
structure, as illustrated below in Figure 1. 
First, MDCH has established a Community Values 
Advisory Board to represent Michigan citizens,17 and 
provide guidance on overarching policies, including 
the types of research that would be seen as proper 
by Michigan laypeople. Second, a Scientific Advisory 
Board reviews the scientific merit of all research pro-
posals. Third, IRBs conduct reviews both at MDCH 
and at the institution where the research is to be con-
ducted. The MDCH IRB reviews proposals not only 
for compliance with regulations governing research, 
but also for concerns related to groups, not just indi-
viduals. Concerns might include research that certain 
populations may find morally objectionable or research 
that could disparage, embarrass, or conflict with cul-
tural mores of certain groups. Finally, the BioTrust 
can decide whether or not the proposed research is a 
worthy use of a non-renewable resource. 
Conclusion
Consistent with ethical principles, public health agen-
cies must often balance the common good and individ-
ual rights when exercising their authorities. Concern-
ing the Michigan BioTrust, this means balancing the 
public benefit from research using DBS with fair treat-
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ment and respect for individuals’ autonomy. Michi-
gan’s effort involved over two years of planning. The 
notion of storing DBS indefinitely for possible future 
research was first recommended in 1999 by the Gov-
ernor-appointed Michigan Commission on Genetic 
Privacy and Progress.18 Since then, staff, experts, and 
community members have invested countless hours 
to develop the Michigan BioTrust for Health. These 
individuals continue to evaluate, develop, and refine 
the process and related aspects to meet objectives 
and respond to new developments. These efforts have 
led to substantial support and minimal opposition or 
complaints to prior and ongoing research involving 
DBS specimens in Michigan.
Our hope is that other states can benefit from Michi-
gan’s experience in exploring and developing opportu-
nities for using DBS. We advise other jurisdictions to 
proceed thoughtfully to develop these opportunities, 
to listen respectfully to others, to take the time neces-
sary to identify, weigh and balance interests, and to 
educate the public about the purposes of public health 
research and protections for individuals.
Note
The opinions in this article do not necessarily represent the views 
of the State of Michigan or the Michigan Department of Commu-
nity Health.
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